ClinicalTrials.gg
CompletedNCT02082327Updated Jun 18, 2014

A Phase 1 Study To Evaluate the Safety of Migalastat Hydrochloride Given Intravenously to Healthy Volunteers

A Phase 1 interventional study of IV migalastat HCl and IV placebo in Fabry Disease, sponsored by Amicus Therapeutics. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-06-18.

Sponsored by Amicus Therapeutics (part of BioMarin Pharmaceutical) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing migalastat in Fabry Disease — 2 open to participants now, 3 under way, 3 of them phase 3. migalastat · Fabry Disease.

Enrollment
7th of 20
31 · median 20
Started
2014
the only one that year
Phase 1
3 of 20
none open now
Registered
12th of 20
by date
Lead sponsor
17 of 20
Amicus Therapeutics

Among the 20 studies testing migalastat in Fabry Disease, this one is the 7th largest by enrollment, is the only one that started in 2014, is one of 3 in phase 1, and was the 12th registered.

Fabry Disease

244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.

Browse Fabry Disease studies →

Open to participants now

2 of the 20 studies testing migalastat in Fabry Disease are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About migalastat

migalastat: first FDA approval 2018 (GALAFOLD), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 44 Fabry Disease studies recruiting now, 31 (70%) set no upper age limit and 11 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing migalastat in Fabry Disease, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of IV migalastat HCl alone and to determine absolute bioavailability for oral migalastat HCl as compared to IV administered migalastat HCl in healthy volunteers. The data from this study will help us understand how migalastat works in the body and will help us determine what would be an effective dose in future studies with migalastat hydrochloride.

03

Conditions studied

  • Fabry Disease

Keywords

  • Fabry Disease
  • Fabry
  • Lysosomal storage disorders
  • LSD
  • Amicus
  • migalastat HCl
  • migalastat
  • AT1001
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females between 18 and 45 years of age.
  • Body weight range ≥ 50 kg ≤ 100 kg and within the range 18.5 - 29.9 kg/m2.
  • Healthy as determined by a responsible and experienced physician, based on a medial evaluation.
  • Male and female subjects of agree to adhere to the requirements.
  • Capable of giving written .

Exclusion criteria

Exclusion Criteria:

  • History of sensitivity to migalastat HCl or related iminosugars (eg, miglitol, miglustat), or other significant drug allergy.
  • Past medical history, or physical examination findings, of abnormalities that may put the subject at risk or interfere with outcome variables.
  • Positive pre-study drug/alcohol screen.
  • Pregnant or lactating females.
  • The subject has participated in a clinical trial and has received an product within 60 days prior to the first dosing day in the current study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    0.3 mg/kg

    IV infusion of migalastat HCl or placebo

    Drug: IV migalastat HCl · Drug: IV placebo

  • Experimental
    1 mg/kg

    IV infusion of migalastat HCl or placebo

    Drug: IV migalastat HCl · Drug: IV placebo

  • Experimental
    10 mg/kg

    IV infusion of migalastat HCl or placebo

    Drug: IV migalastat HCl · Drug: IV placebo

  • Experimental
    150 mg IV

    150 mg single IV infusion

    Drug: IV migalastat HCl · Drug: oral migalastat HCl

  • Experimental
    150 mg oral

    150 mg single oral dose

    Drug: IV migalastat HCl · Drug: oral migalastat HCl

Interventions

06

What researchers measure

Primary outcomes

  1. Plasma pharmacokinetics of migalastat

    To investigate the effect on the body of migalastat following a single 2 hour IV infusion in healthy subjects.

    Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2.0, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48

  2. Safety and tolerability of migalastat

    Adverse events, clinical laboratory test values, vital signs, ECG, physical examinations

    Time frame: 48 hours

Secondary outcomes

  1. Plasma pharmacokinetics of migalastat

    To assess the dose proportionality of migalastat following a single 2 hour IV infusion

    Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2.0, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48

  2. Urinary pharmacokinetics

    To estimate the urinary excretion of unchanged migalastat following a single 2 hour IV infusion in healthy subjects

    Time frame: Pre dose, between 0-6, 6-12 and 12-24 hours after start of infusion

07

Study locations

1 site
  • PRA International
    Groningen, 9713 GZ, Netherlands
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2014, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2014
First posted
Mar 10, 2014
Start
Mar 2014
Primary completionActual
Jun 2014
CompletionActual
Jun 2014
Last update
Jun 18, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02082327
Responsible party
Sponsor
First posted
Mar 10, 2014
Start date
Mar 2014
Primary completion
Jun 2014
Completion
Jun 2014
Last update
Jun 18, 2014

Study contacts

Medical Monitor Clinical Research
study director · Amicus Therapeutics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Migalastat

Start the discussion